EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access · CC BY-NC 4.0

Real-world outcomes of intrapleural platinum-based chemotherapy in lung cancer patients with symptomatic malignant pleural effusion: A multicenter cohort study

Real-World-Ergebnisse einer intrapleuralen platinbasierten Chemotherapie bei Lungenkrebspatient:innen mit symptomatischem malignem Pleuraerguss: multizentrische Kohortenstudie

Chang Qi iD, Yalun Li, Ran Wang, Yi Xiang, Hailong Wei, Yong Cao, Ling Peng, Changyi Li, Huifang Song, Hui Ren, Li Jiang, Ran Li und 19 weitere

Therapeutic Advances in Respiratory Disease · 2026-10 · 20

DOI: 10.1177/17534666261499218 ↗

Auf einen Blick

Bei 391 Patient:innen mit symptomatischem malignem Pleuraerguss war IPC plus intrapleurale platinbasierte Chemotherapie mit besserer pleuraler Kontrolle verbunden als IPC allein. Die Sicherheit war vergleichbar.

Fragestellung

Wie wirksam und sicher ist IPC in Kombination mit intrapleuraler platinbasierter Chemotherapie bei Lungenkrebspatient:innen mit symptomatischem malignem Pleuraerguss?

Methode

Multizentrische retrospektive Real-World-Kohortenstudie in 27 Zentren; Vergleich von IPC allein, IPC plus platinbasierter Chemotherapie und IPC plus anderen intrapleuralen Substanzen; PSM als Sensitivitätsanalyse.

Ergebnisse

Von 391 Patient:innen erhielten 229 IPC allein, 93 IPC plus platinbasierte Chemotherapie und 69 andere intrapleurale Substanzen. Gegenüber IPC allein: MPE-PFS HR 0,64 (95 %-KI 0,46–0,88; P = 0,006), OS HR 0,69 (95 %-KI 0,50–0,97; P = 0,035); 8-Wochen-MPE-ORR 87,1 %.

Schlussfolgerung der Autor:innen

IPC kombiniert mit intrapleuraler platinbasierter Chemotherapie war mit besserer pleuraler Kontrolle und akzeptabler Sicherheit verbunden.

Kernaussagen

  • MPE-PFS und OS waren gegenüber IPC allein besser
  • 8-Wochen-MPE-ORR unter Platintherapie: 87,1 %
  • Nebenwirkungsraten waren vergleichbar

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Multizentrische Studie in der Zeitschrift Therapeutic Advances in Respiratory Disease, online erschienen am 30.10.2026. Verfasst von Chang Qi und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Institute of Respiratory Health an…. Hauptthemen laut MEDLINE: Pleural Effusion, Malignant, Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Antineoplastic Agents. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Noncommunicable Chronic Diseases-National Science and Technology Major Project.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Intrapleural anticancer therapies are increasingly used in clinical practice; however, their additional benefit over indwelling pleural catheter (IPC) alone and the optimal intrapleural strategy remain uncertain. Platinum-based chemotherapy is a common intrapleural approach.

Objective

This study evaluated the efficacy and safety of IPC combined with intrapleural platinum-based chemotherapy in lung cancer patients with symptomatic malignant pleural effusion (MPE).

Design

A multicenter retrospective real-world cohort study.

Methods

Patients with symptomatic MPE from 27 tertiary care centers received IPC alone, IPC combined with intrapleural platinum-based chemotherapy, or IPC combined with other intrapleural agents. The primary endpoint was progression-free survival of MPE (MPE PFS); secondary endpoints were overall survival (OS), the objective response rate of MPE at 8 weeks (8-week MPE ORR), and safety. Propensity score matching (PSM) was performed as a sensitivity analysis.

Results

Of the 391 patients, 229 received IPC alone, 93 received IPC combined with intrapleural platinum-based chemotherapy, and 69 received other intrapleural agents. Among the evaluated strategies, platinum-based chemotherapy was associated with the longest MPE PFS and the highest 8-week MPE ORR (87.1%). Compared with IPC alone, the hazard ratios (HRs) for MPE PFS and OS were 0.64 (95% confidence interval [CI], 0.46 -0.88; P = 0.006) and 0.69 (95% CI, 0.50 -0.97; P = 0.035), respectively. Multivariate Cox regression analysis identified intrapleural platinum-based chemotherapy as an independent predictor of prolonged MPE PFS, but not OS. The associations with MPE PFS and 8-week MPE ORR findings remained significant after PSM, whereas OS did not differ. Within the platinum-based chemotherapy group, regimens that included antiangiogenesis or interleukin-2 did not confer additional benefit over platinum monotherapy. Adverse event rates were comparable between groups (11.3% vs. 17.2%; P = 0.219).

Conclusions

IPC combined with intrapleural platinum-based chemotherapy was associated with improved pleural control and acceptable safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pleural Effusion, MalignantLung NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsAntineoplastic AgentsHumansFemaleRetrospective StudiesMaleAgedMiddle AgedProgression-Free SurvivalCatheters, IndwellingTreatment OutcomeTime Factors

Stichwörter der Autor:innen

indwelling pleural catheterintrapleural chemotherapylung cancermalignant pleural effusionplatinum-based chemotherapy

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Institute of Respiratory Health and Multimorbidity, Institute of Respiratory Health, Frontiers Science C…
  • Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
  • Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
  • Department of Respiratory and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Institute of Respiratory Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Pulmonary and Critical Care Medicine, The people' Hospital of Leshan, Leshan, Sichuan, China.

ORCID-Profile: Chang Qi, Panwen Tian

Förderung

  • Noncommunicable Chronic Diseases-National Science and Technology Major Project

Zitieren

APA

Qi, C., Li, Y., Wang, R., Xiang, Y., Wei, H., Cao, Y., Peng, L., Li, C., Song, H., Ren, H., Jiang, L., Li, R., Zeng, J., Chen, M., Chen, D., Zeng, Y., Wu, X., Liu, Q., Zhang, Y., …, & Tian, P. (2026). Real-world outcomes of intrapleural platinum-based chemotherapy in lung cancer patients with symptomatic malignant pleural effusion: A multicenter cohort study. Therapeutic Advances in Respiratory Disease, 20. https://doi.org/10.1177/17534666261499218

Vancouver

Qi C, Li Y, Wang R, Xiang Y, Wei H, Cao Y, et al. Real-world outcomes of intrapleural platinum-based chemotherapy in lung cancer patients with symptomatic malignant pleural effusion: A multicenter cohort study. Therapeutic Advances in Respiratory Disease. 2026;20. doi:10.1177/17534666261499218

BibTeX
@article{Qi2026,
  author = {Qi, Chang and Li, Yalun and Wang, Ran and Xiang, Yi and Wei, Hailong and Cao, Yong and Peng, Ling and Li, Changyi and Song, Huifang and Ren, Hui and Jiang, Li and Li, Ran and Zeng, Jia and Chen, Minjiang and Chen, Dehe and Zeng, Yunxiang and Wu, Xueling and Liu, Qinghua and Zhang, Yi and Liao, Huai and Zhou, Hongmei and Huang, Na and Wu, Junhua and Wang, Pingfei and Qiu, Rong and Deng, Taibing and Liu, Shuanglin and Zhang, Yuan and Wolf, Jürgen and Li, Weimin and Tian, Panwen},
  title = {Real-world outcomes of intrapleural platinum-based chemotherapy in lung cancer patients with symptomatic malignant pleural effusion: A multicenter cohort study},
  journal = {Therapeutic Advances in Respiratory Disease},
  year = {2026},
  volume = {20},
  doi = {10.1177/17534666261499218}
}
Kostenlos starten →